Navigation Links
Silencing signals sent by parasite could aid sleeping sickness fight
Date:12/15/2013

A new discovery by scientists could help combat the spread of sleeping sickness.

Insights into how the parasites that cause the disease are able to communicate with one another could help limit the spread of the infection.

The findings suggest that new drugs could be designed to disrupt the flow of messages sent between these infectious microorganisms.

Sleeping sickness so named because it disrupts sleep patterns is transmitted by the bite of the tsetse fly, and more than 69 million people in Africa are at risk of infection. Untreated, it can damage the nervous system, leading to coma, organ failure and death.

During infection, the parasites known as African trypanosomes multiply in the bloodstream and communicate with each other by releasing a small molecule. When levels of this molecule become sufficiently high, this acts as a signal for the parasites to stop replicating and to change into a form that can be picked up by biting flies and spread.

A team led by researchers at the University of Edinburgh were able to uncover key components of the parasites' messaging system. They used a technique known as gene silencing, to identify those genes that are used to respond to the communication signals and the mechanisms involved.

Professor Keith Matthews, of the University of Edinburgh's School of Biological Sciences, who led the research, said: "Parasites are adept at communicating with one another to promote their survival in our bodies and ensure their spread but by manipulating their messages, new ways to combat these infections are likely to emerge."

The research, carried out in collaboration with the University of Dundee, was published in the journal Nature, and funded by the Wellcome Trust.


'/>"/>

Contact: Catriona Kelly
Catriona.Kelly@ed.ac.uk
44-131-651-4401
University of Edinburgh
Source:Eurekalert  

Page: 1

Related biology news :

1. Gene-silencing data now publicly available to help scientists better understand disease
2. Gene-silencing study finds new targets for Parkinsons disease
3. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
4. CSHL researchers solve structure of human protein critical for silencing genes
5. Plant research reveals new role for gene silencing protein
6. A powder to enhance NMR signals
7. How living cells solved a needle in a haystack problem to produce electrical signals
8. Artifact suppression and analysis of brain activities with EEG signals
9. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
10. Researchers discover a missing link in signals contributing to neurodegeneration
11. Social bees mark dangerous flowers with chemical signals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Silencing signals sent by parasite could aid sleeping sickness fight
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... The first study to analyze the complex ingredients in ... that these pop-into-the-mouth replacements for cigarettes in places where ... diseases and other problems. The report appears in ACS,s ... John V. Goodpaster and colleagues point out that the ...
... Mass. (March 16, 2011) Renowned cancer researchers Robert ... Hanahan, Director of the Swiss Institute for Experimental Cancer ... of Cancer," which has influenced the study of cancer ... decade. Published in January 2000, their original work, ...
... way the parasite that causes malaria reproduces could lead ... the disease. Scientists studying the disease have found ... from transmitting from person to person. Researchers at ... at a stage of its development in which it ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Enable CyberKnife Centers ... Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... the field of radiosurgery,announced today that Oklahoma CyberKnife LLC, ... reduced treatment,planning and delivery times over the last two ...
... announced today,that its lead product ATIR(TM) has been ... Agency (EMEA) for the prevention of acute,Graft versus ... "Following the orphan drug designation granted by ... another important milestone in the development of,ATIR(TM) as ...
... China indicates that genetically modified cotton, altered to express the ... but also reduces pests among other nearby crops that have ... new ideas for controlling pests and maximizing crop yields in ... the journal Science on Friday, 19 September. ...
Cached Biology Technology:Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2GM crops protect neighbors from pests 2
...
Mouse Cell Line Slides...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: